Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by allegations of poorly done and fraudulent research.

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate simufilam. Read more here.

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its first phase 3 test in mild-to-moderate Alzheimer's and a second study has now been halted, leading to an 84% drop in its share price.

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”